Given the complex expression of purinergic mediators in epithelial, stromal, and immune compartments, receptor blockade may not only impair the specific signaling pathway but also modulate the tumor microenvironment impacting other purinergic receptors. The gene discussed is P2RY1; the disease is neoplasm.